Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026

Shares successful Vikinig Therapeutics (NASDAQ: VKTX) roseate by 16.5% successful February, according to information from S&P Global Market Intelligence. The determination helped the banal retrieve successful 2026, and astatine the clip of writing, it's lone down by a debased single-digit percent this year. The summation successful February followed the company's fourth-quarter net merchandise and firm update.

As ever, with smaller-market-cap biotech companies, the needle mover for their banal is pipeline developments. For Viking Therapeutics, it's its VK2735 improvement program. The dual GLP-1/GIP agonist (a people of drugs revolutionizing the attraction of obesity and diabetes) is successful trials successful some subcutaneous (under the skin) and oral forms for some indications.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Given the advantages of oral weight-loss pills (they debar injections, tin beryllium stored astatine country temperature, and are casual to take), astir of the excitement centers connected the oral formulation of VK2735. However, the institution disappointed the marketplace past August with its top-line results from a Phase 2 VENTURE (oral VK2735) proceedings successful obesity. While the value nonaccomplishment information (up to 12.2% mean value nonaccomplishment aft conscionable 13 weeks) was impressive, the information and tolerability (20% discontinuation complaint owed to adverse events successful the treated group) was not. There is ever a interest astir gastrointestinal issues with oral formulations, and astir of the issues successful the Phase 2 proceedings came down to things similar nausea, vomiting, and diarrhea.

As previously discussed, the VENTURE proceedings had assertive titration, and the treated radical didn't person overmuch clip to set to the attraction (a 13-week trial). The discontinuation complaint owed to an adverse lawsuit successful the placebo radical was 13%, suggesting the wide cohort had immoderate challenging characteristics. Consequently, absorption isn't giving up connected the oral VK2735 formulation, and it had bully quality for investors connected that front.

First, the institution initiated a attraction and modulation survey successful the 4th quarter, successful which participants volition initially person VK2735 subcutaneously, past modulation to a attraction dosage successful subcutaneous oregon oral form. Management announced that "This survey is afloat enrolled and we look guardant to announcing the results successful the 3rd 4th of 2026."